Vanguard disaggregates holdings; reports 0 shares in Collegium (COLL)
Rhea-AI Filing Summary
Collegium Pharmaceutical Inc amendment: The Vanguard Group reports 0 shares beneficially owned of Collegium common stock following an internal realignment. The filing states that certain Vanguard subsidiaries will report ownership separately in accordance with SEC Release No. 34-39538 (January 12, 1998).
The disclosure lists 0 shares and 0% voting and dispositive power in the issuer’s common stock and is signed by Vanguard’s Head of Global Fund Administration.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated holdings; beneficial ownership now zero.
The Vanguard Group states its internal realignment caused certain subsidiaries to report separately, and it no longer is deemed to beneficially own the securities formerly reported under the parent. The filing cites January 12, 1998 SEC Release No. 34-39538.
Cash-flow treatment and any subordinate holder quantities are not listed; subsequent filings by the disaggregated entities may show new beneficial ownership entries.
FAQ
What does Vanguard’s Schedule 13G/A say about COLL ownership?
Why did Vanguard change its ownership reporting for COLL?
Who signed the amendment and when was it filed?